These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 24079451)
1. Allosteric inactivation of a trypsin-like serine protease by an antibody binding to the 37- and 70-loops. Kromann-Hansen T; Lund IK; Liu Z; Andreasen PA; Høyer-Hansen G; Sørensen HP Biochemistry; 2013 Oct; 52(40):7114-26. PubMed ID: 24079451 [TBL] [Abstract][Full Text] [Related]
2. Interconversion of active and inactive conformations of urokinase-type plasminogen activator. Liu Z; Kromann-Hansen T; Lund IK; Hosseini M; Jensen KJ; Høyer-Hansen G; Andreasen PA; Sørensen HP Biochemistry; 2012 Oct; 51(39):7804-11. PubMed ID: 22950516 [TBL] [Abstract][Full Text] [Related]
3. Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies. Botkjaer KA; Fogh S; Bekes EC; Chen Z; Blouse GE; Jensen JM; Mortensen KK; Huang M; Deryugina E; Quigley JP; Declerck PJ; Andreasen PA Biochem J; 2011 Aug; 438(1):39-51. PubMed ID: 21635223 [TBL] [Abstract][Full Text] [Related]
4. Ligand binding modulates the structural dynamics and activity of urokinase-type plasminogen activator: A possible mechanism of plasminogen activation. Kromann-Hansen T; Lange EL; Lund IK; Høyer-Hansen G; Andreasen PA; Komives EA PLoS One; 2018; 13(2):e0192661. PubMed ID: 29420634 [TBL] [Abstract][Full Text] [Related]
5. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site. Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354 [TBL] [Abstract][Full Text] [Related]
6. Influence of cofactor binding and active site occupancy on the conformation of the macromolecular substrate exosite of factor VIIa. Dickinson CD; Shobe J; Ruf W J Mol Biol; 1998 Apr; 277(4):959-71. PubMed ID: 9545384 [TBL] [Abstract][Full Text] [Related]
7. Spontaneous inactivation of human tryptase involves conformational changes consistent with conversion of the active site to a zymogen-like structure. Selwood T; McCaslin DR; Schechter NM Biochemistry; 1998 Sep; 37(38):13174-83. PubMed ID: 9748324 [TBL] [Abstract][Full Text] [Related]
9. Binding of nonphysiological protein and peptide substrates to proteases: differences between urokinase-type plasminogen activator and trypsin and contributions to the evolution of regulated proteolysis. Bergstrom RC; Coombs GS; Ye S; Madison EL; Goldsmith EJ; Corey DR Biochemistry; 2003 May; 42(18):5395-402. PubMed ID: 12731881 [TBL] [Abstract][Full Text] [Related]
11. Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases. Wang Q; Shaltiel S BMC Biochem; 2003 Jul; 4():5. PubMed ID: 12848892 [TBL] [Abstract][Full Text] [Related]
12. Structural and mechanistic insight into how antibodies inhibit serine proteases. Ganesan R; Eigenbrot C; Kirchhofer D Biochem J; 2010 Sep; 430(2):179-89. PubMed ID: 20704569 [TBL] [Abstract][Full Text] [Related]
13. Unraveling the allosteric mechanism of serine protease inhibition by an antibody. Ganesan R; Eigenbrot C; Wu Y; Liang WC; Shia S; Lipari MT; Kirchhofer D Structure; 2009 Dec; 17(12):1614-1624. PubMed ID: 20004165 [TBL] [Abstract][Full Text] [Related]
14. Structure of human pro-chymase: a model for the activating transition of granule-associated proteases. Reiling KK; Krucinski J; Miercke LJ; Raymond WW; Caughey GH; Stroud RM Biochemistry; 2003 Mar; 42(9):2616-24. PubMed ID: 12614156 [TBL] [Abstract][Full Text] [Related]
15. Potent and selective inhibition of membrane-type serine protease 1 by human single-chain antibodies. Sun J; Pons J; Craik CS Biochemistry; 2003 Feb; 42(4):892-900. PubMed ID: 12549907 [TBL] [Abstract][Full Text] [Related]
16. Elucidation of the binding regions of PAI-1 neutralizing antibodies using chimeric variants of human and rat PAI-1. Bijnens AP; Ngo TH; Gils A; Dewaele J; Knockaert I; Stassen JM; Declerck PJ Thromb Haemost; 2001 May; 85(5):866-74. PubMed ID: 11372681 [TBL] [Abstract][Full Text] [Related]
17. An enzyme-linked immunosorbent assay for urokinase-type plasminogen activator (u-PA) and mutants and chimeras containing the serine protease domain of u-PA. Declerck PJ; Van Keer L; Verstreken M; Collen D Thromb Haemost; 1992 Jan; 67(1):95-100. PubMed ID: 1377417 [TBL] [Abstract][Full Text] [Related]
18. Epitope mapping of the anti-urokinase monoclonal antibody 5B4 by isolated domains of urokinase. Corti A; Sarubbi E; Soffientini A; Nolli ML; Zanni A; Galimberti M; Parenti F; Cassani G Thromb Haemost; 1989 Nov; 62(3):934-9. PubMed ID: 2480654 [TBL] [Abstract][Full Text] [Related]
19. Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies. Rasch MG; Pass J; Illemann M; Høyer-Hansen G; Lund IK J Immunol Methods; 2008 Nov; 339(1):55-65. PubMed ID: 18761343 [TBL] [Abstract][Full Text] [Related]
20. Selection of High-Affinity Peptidic Serine Protease Inhibitors with Increased Binding Entropy from a Back-Flip Library of Peptide-Protease Fusions. Sørensen HP; Xu P; Jiang L; Kromann-Hansen T; Jensen KJ; Huang M; Andreasen PA J Mol Biol; 2015 Sep; 427(19):3110-22. PubMed ID: 26281711 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]